Genetic modifiers of Predict-HD phenotypes
Predict-HD 表型的遗传修饰剂
基本信息
- 批准号:8920170
- 负责人:
- 金额:$ 81.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:AgeAge of OnsetBiologicalBrainBrain imagingCAG repeatClinicalClinical TrialsCognitiveCollectionComplementConceptionsDNA Sequence AnalysisDataData SetDiagnosisDiagnosticDiseaseDisease PathwayEnhancersEuropeanGenderGenesGeneticGenotypeGrantHaplotypesHealthHumanHuntington DiseaseImageImpaired cognitionIndividualInheritedLeadLengthMeasurementMeasuresModificationMotorMutationNatureObservational StudyPathogenesisPathway interactionsPatientsPhenotypePredispositionProcessQuantitative Trait LociRegistriesRelative (related person)ResearchResidual stateResourcesRisk FactorsSamplingSeriesSymptomsTestingTherapeuticTimeVariantbasecognitive functiondisease phenotypeexomeexome sequencingexpectationfollow-upgenetic analysisgenetic variantgenome wide association studygenome-widehuman Huntingtin proteinmiddle agemotor impairmentmutantnervous system disordertherapeutic developmenttool
项目摘要
DESCRIPTION (provided by applicant): Huntington's disease (HD) is caused by a CAG expansion mutation whose length is the primary determinant of the age at which diagnostic motor signs emerge, typically in mid-life. The length of the CAG repeat is also correlated with age of onset of cognitive or psychiatric clinical signs in those who present first with these features. Thus, CAG repeat length influences the rate with which biological changes in HD that begin early, due to the expression of mutant huntingtin, lead much later to motor, cognitive or psychiatric onset, although not all steps in each of these three pathogenic processes are likely to be identical. However, the age at onset of motor signs, and likely the timing of cognitive, psychiatric and imaging abnormalities, is influenced by other as yet unidentified genetic factors, not as independent risk factors but as modifiers, i.e., suppressors or enhancers of phenotypes dependent on the presence of an expanded CAG repeat. PREDICT-HD, which was established as an observational study to investigate the effects of the HD mutation during the decades prior to diagnosis, has accumulated a wealth of data in various domains, including brain imaging, motor signs, cognitive disturbance and psychiatric manifestations, that represent a valuable resource for identifying potential modifiers. Via the Center for Inherited Disease Research (CIDR), we have recently generated genome-wide SNP data for PREDICT-HD, and we have complemented these data with genome-wide SNP data for more than 6,000 HD individuals from the Huntington Study Group COHORT study, the European Huntington Disease Network's Registry study and a collection of banked post-mortem HD brains. A coordinated strategy using PREDICT-HD in combination with these other datasets offers the opportunity to identify genetic modifiers that influence the disease pathway(s) triggered by the HD mutation by enhancing or suppressing its timing and/or modifying its phenotypic expression. To identify genetic factors that alter the course of HD, we will use a combination of genome-wide association (GWA) analysis of common variants to quantitative HD phenotypes and analysis of rare SNPS identified by whole exome sequencing of 'extreme' individuals whose phenotypes differ substantially from those expected from their CAG-length and age. Completion of our aims will advance HD research toward effective therapeutics, as the identification of modifier genes, which alter the rate or expression of the disease in human patients, could provide 'pre-validated' targets for therapeutic development as well as a new tool for stratifying clinical trials to maximie their informativeness.
描述(由申请人提供):亨廷顿病(HD)由CAG扩增突变引起,其长度是诊断性运动体征出现的年龄的主要决定因素,通常在中年。CAG重复序列的长度也与首次出现认知或精神临床体征的患者的发病年龄相关。因此,CAG重复序列长度影响HD中的生物学变化的速率,所述生物学变化由于突变亨廷顿蛋白的表达而开始较早,导致运动、认知或精神病发作较晚,尽管这三个致病过程中的每一个中的所有步骤都可能是相同的。然而,运动体征发作时的年龄,以及认知、精神和影像学异常的可能时间,受到其他尚未确定的遗传因素的影响,这些因素不是独立的风险因素,而是修饰因素,即,依赖于扩增的CAG重复序列的存在的表型的抑制子或增强子。PREDICT-HD是一项观察性研究,旨在调查HD突变在诊断前几十年的影响,在各个领域积累了丰富的数据,包括脑成像,运动体征,认知障碍和精神病学表现,这是识别潜在修饰剂的宝贵资源。通过遗传性疾病研究中心(CIDR),我们最近生成了PREDICT-HD的全基因组SNP数据,并将这些数据与来自亨廷顿研究组COHORT研究、欧洲亨廷顿疾病网络登记研究和一组储存的死后HD大脑的6,000多名HD个体的全基因组SNP数据进行了补充。使用PREDICT-HD与这些其他数据集组合的协调策略提供了鉴定遗传修饰剂的机会,所述遗传修饰剂通过增强或抑制其时机和/或修饰其表型表达来影响由HD突变触发的疾病途径。为了确定改变HD病程的遗传因素,我们将使用全基因组关联(GWA)分析常见变异的定量HD表型和分析罕见SNPS的组合,通过全外显子组测序确定的“极端”个体的表型与其CAG长度和年龄的预期有很大不同。我们的目标的完成将推进HD研究向有效的治疗方法,作为修饰基因的鉴定,改变人类患者的疾病的速率或表达,可以提供“预先验证”的治疗发展目标,以及一个新的工具,分层临床试验,以最大限度地提高其信息量。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES F GUSELLA其他文献
JAMES F GUSELLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES F GUSELLA', 18)}}的其他基金
Genetic Mechanisms Controlling Resilience to Huntington's Disease
控制亨廷顿病抵抗力的遗传机制
- 批准号:
10531136 - 财政年份:2021
- 资助金额:
$ 81.05万 - 项目类别:
Genetic Mechanisms Controlling Resilience to Huntington's Disease
控制亨廷顿病抵抗力的遗传机制
- 批准号:
10388685 - 财政年份:2021
- 资助金额:
$ 81.05万 - 项目类别:
Genetic Mechanisms Controlling Resilience to Huntington's Disease
控制亨廷顿病抵抗力的遗传机制
- 批准号:
10889305 - 财政年份:2021
- 资助金额:
$ 81.05万 - 项目类别:
Dissecting recurrent microdeletion syndromes using dual-guide genome editing
使用双引导基因组编辑剖析复发性微缺失综合征
- 批准号:
8944343 - 财政年份:2015
- 资助金额:
$ 81.05万 - 项目类别:
Dissecting recurrent microdeletion syndromes using dual-guide genome editing
使用双引导基因组编辑剖析复发性微缺失综合征
- 批准号:
9087365 - 财政年份:2015
- 资助金额:
$ 81.05万 - 项目类别:
相似海外基金
Determining the mechanism of action of cis-acting modifiers on the age of onset of Huntington Disease
确定顺式作用修饰剂对亨廷顿病发病年龄的作用机制
- 批准号:
417256 - 财政年份:2019
- 资助金额:
$ 81.05万 - 项目类别:
Studentship Programs
Effect of age of onset of contraception use on brain functioning.
避孕开始年龄对大脑功能的影响。
- 批准号:
511267-2017 - 财政年份:2017
- 资助金额:
$ 81.05万 - 项目类别:
University Undergraduate Student Research Awards
Non-random occurrence and early age of onset of diverse lymphoid cancers in families supports the existence of genetic risk factors for multiple lymphoid cancers.
家族中多种淋巴癌的非随机发生和发病年龄较早,支持多种淋巴癌存在遗传危险因素。
- 批准号:
347105 - 财政年份:2016
- 资助金额:
$ 81.05万 - 项目类别:
Polish-German Child Bilingualism: The Role of Age of Onset for Long-Term Achievement
波兰-德国儿童双语:发病年龄对长期成就的作用
- 批准号:
277135691 - 财政年份:2015
- 资助金额:
$ 81.05万 - 项目类别:
Research Grants
Bioinformatics strategies to relate age of onset with gene-gene interaction
将发病年龄与基因间相互作用联系起来的生物信息学策略
- 批准号:
9097781 - 财政年份:2015
- 资助金额:
$ 81.05万 - 项目类别:
Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration
早期 AD 发病年龄:临床异质性和网络退化
- 批准号:
9212684 - 财政年份:2014
- 资助金额:
$ 81.05万 - 项目类别:
Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration
早期 AD 发病年龄:临床异质性和网络退化
- 批准号:
8696557 - 财政年份:2014
- 资助金额:
$ 81.05万 - 项目类别:
Effects of delaying age of onset of binge drinking on adolescent brain development: A proposal to add neuroimaing measures to the CO-Venture Trial.
延迟酗酒的发病年龄对青少年大脑发育的影响:在 CO-Venture 试验中添加神经影像测量的建议。
- 批准号:
267251 - 财政年份:2012
- 资助金额:
$ 81.05万 - 项目类别:
Operating Grants
Stress Effects on Alcohol Consumption: Age of onset and genes in heavy drinkers
压力对饮酒的影响:酗酒者的发病年龄和基因
- 批准号:
8606722 - 财政年份:2012
- 资助金额:
$ 81.05万 - 项目类别:
Marijuana: Neurobiologic Correlates of Age of Onset
大麻:发病年龄的神经生物学相关性
- 批准号:
8644793 - 财政年份:2012
- 资助金额:
$ 81.05万 - 项目类别: